Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome.
TM Kuzel, HH Roenigk Jr, E Samuelson… - Journal of clinical …, 1995 - ascopubs.org
TM Kuzel, HH Roenigk Jr, E Samuelson, JJ Herrmann, A Hurria, AW Rademaker, ST Rosen
Journal of clinical oncology, 1995•ascopubs.orgPURPOSE To investigate the efficacy of combined topical therapy and systemic interferon
alfa-2a in patients with mycosis fungoides (MF) and the Sézary syndrome (SS). PATIENTS
AND METHODS Between December 1987 and April 1993, 39 patients with all stages of MF
and SS were treated with combined phototherapy and systemic interferon alfa-2a as part of
two institutional studies. The initial phase I study of 15 patients established the maximum-
tolerated dose of interferon and has been previously reported. Subsequently, 24 patients …
alfa-2a in patients with mycosis fungoides (MF) and the Sézary syndrome (SS). PATIENTS
AND METHODS Between December 1987 and April 1993, 39 patients with all stages of MF
and SS were treated with combined phototherapy and systemic interferon alfa-2a as part of
two institutional studies. The initial phase I study of 15 patients established the maximum-
tolerated dose of interferon and has been previously reported. Subsequently, 24 patients …
PURPOSE
To investigate the efficacy of combined topical therapy and systemic interferon alfa-2a in patients with mycosis fungoides (MF) and the Sézary syndrome (SS).
PATIENTS AND METHODS
Between December 1987 and April 1993, 39 patients with all stages of MF and SS were treated with combined phototherapy and systemic interferon alfa-2a as part of two institutional studies. The initial phase I study of 15 patients established the maximum-tolerated dose of interferon and has been previously reported. Subsequently, 24 patients have been entered onto a phase II trial. Long-term follow-up data are provided for both studies.
RESULTS
The median follow-up duration for the entire cohort is 28 months. Patients with all stages of disease were enrolled (stage IB, n = 14; IIA, n = 5; IIB, n = 6; III, n = 8; IVA, n = 5; IVB, n = 1). Thirty-four patients had received previous therapy. Overall, 36 of 39 patients achieved a complete response (CR; 62%) or partial response (28%) to therapy. The median response duration is 28 months (range, 1 to 64). Twenty-nine of 39 patients are alive, with a median survival duration of 62 months (range, 1 to 66).
CONCLUSION
Interferon alfa-2a combined with phototherapy is an effective, safe, durable therapy for MF and SS.
ASCO Publications